Related Experiment Videos

[Antimicrobial activity of cefpiramide to fresh clinical isolates]

K Deguchi1, N Yokota, M Koguchi

  • 1Section of Studies, Tokyo Clinical Research Center.

Insights

Cefpiramide (CPM) shows reduced effectiveness against some resistant bacteria like MRSA and Pseudomonas. However, CPM remains clinically useful against most common infections due to its persistent blood levels.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Context:

  • Evaluated antimicrobial activity of cefpiramide (CPM) against 835 clinically isolated microbial strains from Japan in 1990.
  • Compared CPM's minimum inhibitory concentration (MIC) with other cephem antibiotics.
  • Assessed resistance trends in bacteria isolated from patients with various infections.

Purpose:

  • Determine the antimicrobial activity of cefpiramide (CPM) against a diverse range of clinically relevant bacterial strains.
  • Identify shifts in bacterial resistance patterns to CPM compared to the early 1980s.
  • Evaluate the current clinical utility of CPM in light of emerging resistance.

Summary:

  • No resistance to cefpiramide (CPM) was observed in Streptococcus pyogenes, Streptococcus pneumoniae, and anaerobic Gram-positive cocci.
  • Increased resistance to CPM was noted in Staphylococcus aureus, Proteus vulgaris, Pseudomonas aeruginosa, and Haemophilus influenzae compared to earlier studies.
  • Methicillin-resistant S. aureus and resistant Gram-negative bacilli showed high resistance rates, limiting CPM's efficacy in some cases.

Impact:

  • Highlights the growing challenge of antimicrobial resistance, particularly against beta-lactam drugs.
  • Suggests that while CPM faces resistance from certain strains, it retains significant clinical value for common infections.
  • Emphasizes the need for ongoing monitoring of drug resistance and evaluation of antibiotic efficacy over time.

Related Concept Videos